Knockdown of GCH1 significantly activated ferritin autophagy upon erastin treatment, which was reversed by using an autophagy inhibitor
Current FDA-approved weekly injectable GLP-1 options include: Ozempic (semaglutide, Novo Nordisk) for type 2 diabetes Wegovy (semaglutide, Novo Nordisk) for chronic weight management Mounjaro (tirzepatide, Lilly) for type 2 diabetes Zepbound (tirzepatide, Lilly) for chronic weight management Rybelsus (oral semaglutide, Novo Nordisk) for type 2 diabetes Foundayo (orforglipron, Lilly) oral, for weight management (approved April 2026) For patients who struggle specifically with weekly injections, the most practical currently available option is Foundayo (orforglipron) an oral pill requiring no injection at all
7-Day Support: Email, phone, or text support from our research team, including weekend coverage for urgent protocol questions
Current Regulatory Status Overview FDA Classification In 2023, the FDA placed BPC-157 in Category 2 of substances presenting significant safety risks, explicitly prohibiting its use in compounded medications
.webp)
